Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclizumab and Infliximab for Steroid Refractory Acute GVHD
NCT00574470Phase 4Completed
- Sponsor
- University of Iowa
- Start
- Jan 2006
- Primary completion
- Nov 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of daclizumab and infliximab in Acute Graft-Versus-Host Disease (aGVHD), sponsored by University of Iowa. Primary endpoint: Overall Response Rate at 28 days. Started Jan 2006; status: completed.
02
Drugs
daclizumabinfliximab
03
Conditions
Acute Graft-Versus-Host Disease (aGVHD)
Beyond the preview
Go deeper on NCT00574470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00574470.